The clinical use of pharmacogenomic testing in treatment-resistant depression

Simon Kung, Xiaofan Li

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Pharmacogenomic testing is clinically available to assist with medication selection in treatment-resistant depression (TRD). Common tests include the cytochrome P450 (CYP) 2D6 and 2C19 enzymes, the serotonin transporter gene, and the serotonin receptor gene. There are practical recommendations of interventions which can be supported from the literature. Identification of a CYP2D6 poor metabolizer would result in recommending a lower dosage of medications metabolized by CYP2D6, or avoiding the use of CYP2D6 medications. Identification of a serotonin transporter gene short/short genotype suggests more adverse effects, less response, or longer time to respond to selective serotonin reuptake inhibitors (SSRIs), and may warrant focusing treatment with non-SSRIs. Numerous other genotypes have been studied but with mixed implications. The use of pharmacogenomic testing can help the clinician rationalize medication selection and reduce the numerous medication combinations used in TRD. Further research and clinical experience will continue to define the clinical utility of this testing.

Original languageEnglish (US)
Pages (from-to)46-51
Number of pages6
JournalPrimary Psychiatry
Volume17
Issue number5
StatePublished - May 1 2010

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'The clinical use of pharmacogenomic testing in treatment-resistant depression'. Together they form a unique fingerprint.

  • Cite this